World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   12 records for 9 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1
Recruitment statusMain ID Public TitleDate of Registration
Not recruitingNCT02410434
Reducing Lesbian, Gay , Bisexual and Transgender (LGBT) Stigma in Swaziland and Lesotho
30/03/2015
Not recruitingNCT02315690
Evaluation of Targeted Parasite Elimination in Swaziland
08/12/2014
RecruitingNCT01971710
The ACCLAIM Project
13/08/2013
Not recruitingNCT01904994
Link4Health: A Combination Strategy for Linkage and Retention, Swaziland
16/07/2013
RecruitingNCT01891799
Swaziland Safe Generations
28/06/2013
Not recruitingNCT01694862
Benefits and Costs of Integrating Sexual-Reproductive Health and HIV Services in Kenya and Swaziland
21/09/2012
Not recruitingACTRN12611000236998
Enhanced control of hypertension and thrombolysis stroke study 03/03/2011
AuthorisedEUCTR2009-016243-20-BE
Efficacy of BI 10773 versus placebo and sitagliptin over 24 weeks in patients with type 2 diabetes 07/07/2010
Not RecruitingEUCTR2008-008008-42-FR
An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2008-008008-42-IT 05/08/2009
Not RecruitingEUCTR2008-008008-42-DK 30/09/2009
Not AvailableEUCTR2008-008008-42-Outside-EU/EEAA study to check how safe, beneficial and tolerable the drug canakinumab is for patients with SJIA09/03/2012
AuthorisedEUCTR2008-008008-42-BEAn open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations WHO PARTICIPATED IN STUDIES ACZ885G2301 AND ACZ885G2305;AND RESPONSE CHARACTERIZATION STUDY IN CANAKINUMAB TREATMENT-NAÏVE PATIENTS WITH ACTIVE SJIA WITH AND WITHOUT FEVER - G2301E109/04/2009
AuthorisedEUCTR2008-008008-42-GBAn open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations who participated in studies ACZ885G2301 and ACZ885G2305; and response characterisation study in canakinumab treatment-naive patients with active SIJA with and without fever (Cohort 2 (treatment naive patients) only applicable in countries where approved) - G2301E111/09/2009
Not RecruitingEUCTR2008-008008-42-ESEstudio de extensión, abierto, con canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica y manifestaciones sistémicas activas - G2301E101/04/2009
Not RecruitingEUCTR2008-008008-42-HUAn open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations who participated in studies ACZ885G2301 and ACZ885G2305;and response characterization study in canakinumab treatment-naïve patients with active SJIA with and without fever - G2301E107/04/2009
Not RecruitingEUCTR2008-008008-42-ATAn open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations who participated in studies ACZ885G2301 and ACZ885G2305;and response characterization study in canakinumab treatment-naïve patients with active SJIA with and without fever - G2301E130/12/2009
Not RecruitingEUCTR2008-008008-42-DEAn open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations WHO PARTICIPATED IN STUDIES ACZ885G2301 AND ACZ885G2305;AND RESPONSE CHARACTERIZATION STUDY IN CANAKINUMAB TREATMENT-NAÏVE PATIENTS WITH ACTIVE SJIA WITH AND WITHOUT FEVER - G2301E117/04/2009
Not recruitingNCT00891046An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.29/04/2009
Not RecruitingEUCTR2008-008008-42-GRAn open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations - G2301E104/12/2009
Not RecruitingEUCTR2008-008008-42-NLresearch with children with severe reuma25/05/2009
Not RecruitingEUCTR2008-008008-42-SEAn open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations, who participated in studies CACZ885G2301 and CACZ885G2305; and response characterization study in canakinumab treatment-naïve patients with active SJIA with and without fever. - G2301E116/06/2009
19/03/2009
RecruitingNCT00858364
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingEUCTR2007-005792-34-IE 15/04/2009
AuthorisedEUCTR2007-005792-34-ES 05/06/2009
AuthorisedEUCTR2007-005792-34-GR 21/10/2009
AuthorisedEUCTR2007-005792-34-IT 09/11/2009
AuthorisedEUCTR2007-005792-34-SI 10/02/2010
AuthorisedEUCTR2007-005792-34-CZStudy to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 mcg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy22/04/2009
Not RecruitingEUCTR2007-005792-34-ATStudy to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 mcg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy06/05/2009
AuthorisedEUCTR2007-005792-34-GBStudy to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 mcg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy09/04/2009
AuthorisedEUCTR2007-005792-34-BGStudy to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 mcg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy11/02/2010
AuthorisedEUCTR2007-005792-34-DEStudy to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 mcg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy15/06/2009
AuthorisedEUCTR2007-005792-34-BEStudy to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 mcg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy11/05/2009
AuthorisedEUCTR2007-005792-34-NLStudy to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 mcg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy20/07/2009
RecruitingCTRI/2009/091/000800A phase 3 clinical trial to study the long term safety and efficacy of darbepoetin alfa drug in drug induced anemia patients.14-10-2009
05/03/2009
    
1
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history